Soluble Corn Fiber for Promoting Executive Function Study

NCT ID: NCT05066425

Last Updated: 2021-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-02

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching aim of this study is to test the influence of daily consumption of a soluble corn fiber (SCF) known i.e., PROMITOR® Soluble Fibre™ for cognitive function among middle and older-aged adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although regular consumption of soluble dietary fiber has been shown to support multiple markers of gastrointestinal and physical health, the effects of regular fiber consumption for promoting cognitive health remain unclear. Additionally, the GI microbiota-dependent mechanisms by which dietary fiber may impact markers of cognitive function remain understudied. Thus, the overarching aim of this study is to test the influence of daily consumption of a soluble corn fiber (SCF) known i.e., PROMITOR® Soluble Fibre™ for cognitive function among middle and older-aged adults. The primary hypothesis is that daily consumption of dietary fiber over a period of 4 weeks will significantly improve executive function. The secondary hypothesis is that the influence of SCF on cognitive outcomes will be mediated by improvement in GI bacterial taxa and fermentation-end product profiles. These hypotheses will be tested by conducting a 4 week randomized, double-blind, placebo-controlled cross-over study among healthy, i.e., free-living cognitively intact middle-aged and older adults between45-75 years of age. This work is significant because most Americans do not meet their recommended dietary fiber intake and there is a growing interest in understanding the potential benefits of consuming dietary fiber for broader health outcomes including both gastrointestinal and cognitive health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Soluble Corn Fiber

22g Soluble Corn Fiber/day for 4 weeks

Group Type EXPERIMENTAL

Soluble Corn Fiber

Intervention Type DIETARY_SUPPLEMENT

Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks

Maltodextrin

22g Maltodextrin/day for 4 weeks

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soluble Corn Fiber

Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 45-75 years of age
2. Free of cognitive impairment (Mini-Mental State Examination score of higher than 24)
3. Absence of neurological disease
4. Absence of gastrointestinal diseases
5. Absence of prediabetes or diabetes
6. No color blindness
7. Have normal or corrected-to-normal vision
8. No history of antibiotics or smoking over the past 3 months
9. Agree to refrain from taking pre-or probiotic supplements during the study
10. Agree to inform researchers of any changes in chronic medications during the study
11. Body Mass Index (BMI) between 18.5 to 34.9 kg/m2
12. Habitual dietary fiber consumption of ≤12g/d (women) and ≤19 g/d (men) based on DHQ II
13. Not consuming an extreme dietary pattern (e.g., vegan, keto, low FODMAP)
14. No allergies to corn or maltodextrin, eggs, peanuts, tree nuts, wheat and soy
15. Agree to maintain habitual dietary patterns throughout the study period
16. Maintain their current level of physical activity
17. Complete all necessary study questionnaires and to provide stool specimens as required.

Exclusion Criteria

1. \<45 or \>75 years of age
2. Presence of cognitive impairment (Mini-Mental State Examination score of lower than 24)
3. Presence of neurological disease
4. Presence of gastrointestinal diseases
5. Presence of prediabetes or diabetes
6. Color blindness
7. Non normal or uncorrected vision
8. History of antibiotics or smoking over the past 3 months
9. Not agree to refrain from taking pre- or probiotic supplements during the study
10. Not agree to communicate any changes in chronic medications during the study
11. Body Mass Index (BMI) below 18.5 or greater than 34.9 kg/m2
12. Habitual dietary fiber consumption of \>12g/d (women) and \>19 g/d (men) based on DHQ II
13. Consuming an extreme dietary pattern (e.g., vegan, keto, low FODMAP)
14. Allergies to corn and/or maltodextrin
15. Not agree to maintain habitual dietary patterns throughout the study period
16. Not agree to maintain their current level of physical activity
17. Not agree to complete all necessary study questionnaires and to provide stool specimens as required.
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tate and Lyle Ingredients Americas LLC

UNKNOWN

Sponsor Role collaborator

University of Illinois at Urbana-Champaign

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Illinois at Urbana-Champaign

Urbana, Illinois, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Naiman A Khan, PhD, RD

Role: primary

217-300-2197

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21839

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lycopene In Preventing of Prostate Cancer
NCT00006078 COMPLETED PHASE1
Natural Heart Health Supplement Trial
NCT06671769 NOT_YET_RECRUITING PHASE1
Sweet Corn and Carotenoids
NCT06892444 ACTIVE_NOT_RECRUITING NA